

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in managing differentiated... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-86/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-86" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in managing differentiated thyroid cancer" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in managing differentiated thyroid cancer.">
            <meta name="og:description" content="Read the latest article version by Livia Lamartina, Giorgio Grani, Cosimo Durante, Sebastiano Filetti, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="13881">
            <meta name="article-id" content="12811">
            <meta name="dc.title" content="Recent advances in managing differentiated thyroid cancer">
            <meta name="dc.description" content="The main clinical challenge in the management of thyroid cancer is to avoid over-treatment and over-diagnosis in patients with lower-risk disease while promptly identifying those patients with more advanced or high-risk disease requiring aggressive treatment. In recent years, novel clinical and molecular data have emerged, allowing the development of new staging systems, predictive and prognostic tools, and treatment approaches. There has been a notable shift toward more conservative management of low- and intermediate-risk patients, characterized by less extensive surgery, more selective use of radioisotopes (for both diagnostic and therapeutic purposes), and less intensive follow-up. Furthermore, the histologic classification; tumor, node, and metastasis (TNM) staging; and American Thyroid Association risk stratification systems have been refined, and this has increased the number of patients in the low- and intermediate-risk categories. There is now a need for new, prospective data to clarify how these changing practices will impact long-term outcomes of patients with thyroid cancer, and new follow-up strategies and biomarkers are still under investigation. On the other hand, patients with more advanced or high-risk disease have a broader portfolio of options in terms of treatments and therapeutic agents, including multitarget tyrosine kinase inhibitors, more selective BRAF or MEK inhibitors, combination therapies, and immunotherapy.">
            <meta name="dc.subject" content="Thyroid cancer, radioisotopes, TMN staging">
            <meta name="dc.creator" content="Lamartina, Livia">
            <meta name="dc.creator" content="Grani, Giorgio">
            <meta name="dc.creator" content="Durante, Cosimo">
            <meta name="dc.creator" content="Filetti, Sebastiano">
            <meta name="dc.date" content="2018/01/18">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.12811.1">
            <meta name="dc.source" content="F1000Research 2018 7:86">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Thyroid cancer">
            <meta name="prism.keyword" content="radioisotopes">
            <meta name="prism.keyword" content="TMN staging">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/01/18">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="86">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.12811.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-86">
            <meta name="citation_title" content="Recent advances in managing differentiated thyroid cancer">
            <meta name="citation_abstract" content="The main clinical challenge in the management of thyroid cancer is to avoid over-treatment and over-diagnosis in patients with lower-risk disease while promptly identifying those patients with more advanced or high-risk disease requiring aggressive treatment. In recent years, novel clinical and molecular data have emerged, allowing the development of new staging systems, predictive and prognostic tools, and treatment approaches. There has been a notable shift toward more conservative management of low- and intermediate-risk patients, characterized by less extensive surgery, more selective use of radioisotopes (for both diagnostic and therapeutic purposes), and less intensive follow-up. Furthermore, the histologic classification; tumor, node, and metastasis (TNM) staging; and American Thyroid Association risk stratification systems have been refined, and this has increased the number of patients in the low- and intermediate-risk categories. There is now a need for new, prospective data to clarify how these changing practices will impact long-term outcomes of patients with thyroid cancer, and new follow-up strategies and biomarkers are still under investigation. On the other hand, patients with more advanced or high-risk disease have a broader portfolio of options in terms of treatments and therapeutic agents, including multitarget tyrosine kinase inhibitors, more selective BRAF or MEK inhibitors, combination therapies, and immunotherapy.">
            <meta name="citation_description" content="The main clinical challenge in the management of thyroid cancer is to avoid over-treatment and over-diagnosis in patients with lower-risk disease while promptly identifying those patients with more advanced or high-risk disease requiring aggressive treatment. In recent years, novel clinical and molecular data have emerged, allowing the development of new staging systems, predictive and prognostic tools, and treatment approaches. There has been a notable shift toward more conservative management of low- and intermediate-risk patients, characterized by less extensive surgery, more selective use of radioisotopes (for both diagnostic and therapeutic purposes), and less intensive follow-up. Furthermore, the histologic classification; tumor, node, and metastasis (TNM) staging; and American Thyroid Association risk stratification systems have been refined, and this has increased the number of patients in the low- and intermediate-risk categories. There is now a need for new, prospective data to clarify how these changing practices will impact long-term outcomes of patients with thyroid cancer, and new follow-up strategies and biomarkers are still under investigation. On the other hand, patients with more advanced or high-risk disease have a broader portfolio of options in terms of treatments and therapeutic agents, including multitarget tyrosine kinase inhibitors, more selective BRAF or MEK inhibitors, combination therapies, and immunotherapy.">
            <meta name="citation_keywords" content="Thyroid cancer, radioisotopes, TMN staging">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Livia Lamartina">
            <meta name="citation_author_institution" content="Dipartimento di Medicina Interna e Specialit&agrave; Mediche, Universit&agrave; di Roma &ldquo;Sapienza&rdquo;, Viale del Policlinico 155, 00161 Rome, Italy">
            <meta name="citation_author" content="Giorgio Grani">
            <meta name="citation_author_institution" content="Dipartimento di Medicina Interna e Specialit&agrave; Mediche, Universit&agrave; di Roma &ldquo;Sapienza&rdquo;, Viale del Policlinico 155, 00161 Rome, Italy">
            <meta name="citation_author" content="Cosimo Durante">
            <meta name="citation_author_institution" content="Dipartimento di Medicina Interna e Specialit&agrave; Mediche, Universit&agrave; di Roma &ldquo;Sapienza&rdquo;, Viale del Policlinico 155, 00161 Rome, Italy">
            <meta name="citation_author" content="Sebastiano Filetti">
            <meta name="citation_author_institution" content="Dipartimento di Medicina Interna e Specialit&agrave; Mediche, Universit&agrave; di Roma &ldquo;Sapienza&rdquo;, Viale del Policlinico 155, 00161 Rome, Italy">
            <meta name="citation_publication_date" content="2018/01/18">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="86">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.12811.1">
            <meta name="citation_firstpage" content="86">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-86/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-86.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=13881 /> <input type=hidden id=articleId name=articleId value=12811 /> <input type=hidden id=xmlUrl value="/articles/7-86/v1/xml"/> <input type=hidden id=xmlFileName value="-7-86-v1.xml"> <input type=hidden id=article_uuid value=85966746-a33e-4e9e-b337-64a20342bf84 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in managing differentiated thyroid cancer"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.12811.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.12811.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-86"
  },
  "headline": "Recent advances in managing differentiated thyroid cancer",
  "datePublished": "2018-01-18T12:08:08",
  "dateModified": "2018-01-18T12:08:08",
  "author": [
    {
      "@type": "Person",
      "name": "Livia Lamartina"
    },    {
      "@type": "Person",
      "name": "Giorgio Grani"
    },    {
      "@type": "Person",
      "name": "Cosimo Durante"
    },    {
      "@type": "Person",
      "name": "Sebastiano Filetti"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "The main clinical challenge in the management of thyroid cancer is to avoid over-treatment and over-diagnosis in patients with lower-risk disease while promptly identifying those patients with more advanced or high-risk disease requiring aggressive treatment. In recent years, novel clinical and molecular data have emerged, allowing the development of new staging systems, predictive and prognostic tools, and treatment approaches. There has been a notable shift toward more conservative management of low- and intermediate-risk patients, characterized by less extensive surgery, more selective use of radioisotopes (for both diagnostic and therapeutic purposes), and less intensive follow-up. Furthermore, the histologic classification; tumor, node, and metastasis (TNM) staging; and American Thyroid Association risk stratification systems have been refined, and this has increased the number of patients in the low- and intermediate-risk categories. There is now a need for new, prospective data to clarify how these changing practices will impact long-term outcomes of patients with thyroid cancer, and new follow-up strategies and biomarkers are still under investigation. On the other hand, patients with more advanced or high-risk disease have a broader portfolio of options in terms of treatments and therapeutic agents, including multitarget tyrosine kinase inhibitors, more selective BRAF or MEK inhibitors, combination therapies, and immunotherapy."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-86",
            "name": "Recent advances in managing differentiated thyroid cancer"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in managing differentiated thyroid cancer </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=13881 data-id=12811 data-downloads="" data-views="" data-scholar="10.12688/f1000research.12811.1" data-recommended="" data-doi="10.12688/f1000research.12811.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-86/v1/pdf?article_uuid=85966746-a33e-4e9e-b337-64a20342bf84" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-12811-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-12811-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-12811-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Lamartina L, Grani G, Durante C and Filetti S. Recent advances in managing differentiated thyroid cancer [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):86 (<a class=new-orange href="https://doi.org/10.12688/f1000research.12811.1" target=_blank>https://doi.org/10.12688/f1000research.12811.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-12811-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=12811 id=track-article-signin-12811 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/12811?target=/articles/7-86">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=13881 /> <input name=articleId type=hidden value=12811 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in managing differentiated thyroid cancer</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Livia Lamartina,&nbsp;</span><span class="">Giorgio Grani<a href="https://orcid.org/0000-0002-0388-1283" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-0388-1283</div>,&nbsp;</span><span class="">Cosimo Durante,&nbsp;</span><span class=""><a href="mailto:sebastiano.filetti@uniroma1.it" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Sebastiano Filetti</span></a><a href="https://orcid.org/0000-0001-8570-6448" target=_blank id=author-orcid-3><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-3><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-8570-6448</div></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Livia Lamartina,&nbsp;</span><span class="">Giorgio Grani<a href="http://orcid.org/0000-0002-0388-1283" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-0388-1283</div>,&nbsp;</span><span class="">Cosimo Durante,&nbsp;</span><span class=""><a href="mailto:sebastiano.filetti@uniroma1.it" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Sebastiano Filetti</span></a><a href="http://orcid.org/0000-0001-8570-6448" target=_blank id=mauthor-orcid-3><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-3><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-8570-6448</div></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 18 Jan 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.12811.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Dipartimento di Medicina Interna e Specialit&agrave; Mediche, Universit&agrave; di Roma &ldquo;Sapienza&rdquo;, Viale del Policlinico 155, 00161 Rome, Italy<br/> <p> <div class=margin-bottom> Livia Lamartina <br/> <span>Roles: </span> Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Giorgio Grani <br/> <span>Roles: </span> Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Cosimo Durante <br/> <span>Roles: </span> Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Sebastiano Filetti <br/> <span>Roles: </span> Supervision, Writing  Original Draft Preparation, Writing  Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=27816-29983></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=27815-29982></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> The main clinical challenge in the management of thyroid cancer is to avoid over-treatment and over-diagnosis in patients with lower-risk disease while promptly identifying those patients with more advanced or high-risk disease requiring aggressive treatment. In recent years, novel clinical and molecular data have emerged, allowing the development of new staging systems, predictive and prognostic tools, and treatment approaches. There has been a notable shift toward more conservative management of low- and intermediate-risk patients, characterized by less extensive surgery, more selective use of radioisotopes (for both diagnostic and therapeutic purposes), and less intensive follow-up. Furthermore, the histologic classification; tumor, node, and metastasis (TNM) staging; and American Thyroid Association risk stratification systems have been refined, and this has increased the number of patients in the low- and intermediate-risk categories. There is now a need for new, prospective data to clarify how these changing practices will impact long-term outcomes of patients with thyroid cancer, and new follow-up strategies and biomarkers are still under investigation. On the other hand, patients with more advanced or high-risk disease have a broader portfolio of options in terms of treatments and therapeutic agents, including multitarget tyrosine kinase inhibitors, more selective BRAF or MEK inhibitors, combination therapies, and immunotherapy. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Thyroid cancer, radioisotopes, TMN staging </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Sebastiano Filetti (<a href="mailto:sebastiano.filetti@uniroma1.it">sebastiano.filetti@uniroma1.it</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Sebastiano Filetti </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2018 Lamartina L <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Lamartina L, Grani G, Durante C and Filetti S. Recent advances in managing differentiated thyroid cancer [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):86 (<a href="https://doi.org/10.12688/f1000research.12811.1" target=_blank>https://doi.org/10.12688/f1000research.12811.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 18 Jan 2018, <b>7</b>(F1000 Faculty Rev):86 (<a href="https://doi.org/10.12688/f1000research.12811.1" target=_blank>https://doi.org/10.12688/f1000research.12811.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 18 Jan 2018, <b>7</b>(F1000 Faculty Rev):86 (<a href="https://doi.org/10.12688/f1000research.12811.1" target=_blank>https://doi.org/10.12688/f1000research.12811.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d94018e183>Introduction</h2><p class="" id=d94018e186>The incidence of differentiated thyroid cancer (DTC) continues to rise worldwide, mostly because of the growing use of powerful diagnostic tools that permit the discovery of an increasing number of small papillary thyroid cancers (PTCs). Mortality from DTC, however, has changed minimally over the past five decades: the vast majority of patients with DTC have indolent tumors. The main clinical challenge is to avoid over-diagnosis in patients with low-risk disease or benign thyroid nodules while promptly identifying those patients with more advanced or high-risk tumors that require aggressive treatment approaches. In recent years, we have witnessed the emergence of new clinical and molecular data that have allowed the development of new staging systems, new predictive and prognostic tools, and new approaches to treatment. Here, we will review the main advances regarding the staging and management of DTC.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d94018e192>Pathologic definition and staging systems</h2><p class="" id=d94018e195>The fourth edition of the World Health Organization histologic classification of endocrine tumors, published in June 2017<sup><a href="#ref-1">1</a></sup>, contains important revisions, which may have a broad impact on clinical practice. First, the follicular-derived neoplasms now include a new entity within the group of tumors with borderline histological features: the non-invasive follicular thyroid tumor with papillary nuclear features (NIFTP)<sup><a href="#ref-2">2</a>,<a href="#ref-3">3</a></sup>, an encapsulated follicular-variant PTC with no evidence of capsular or vascular invasion. NIFTPs may account for up to 20% of the tumors previously classified as PTCs. The word cancer has been eliminated from the definition of NIFTP to underline its excellent prognosis: no adverse outcomes (such as cancer-related death, distant or regional metastases, and structural or biochemical recurrence) have been recorded for these tumors. The explicitly stated objective is to reduce the intensity of treatment and follow-up and the psychological consequences of the diagnosis of cancer. This entity was first proposed by an international panel of pathologists and other professionals and has been endorsed by the American Thyroid Association (ATA). However, the seemingly excellent outcomes still need to be confirmed in long-term prospective studies. The current evidence is retrospective and of only moderate quality<sup><a href="#ref-2">2</a></sup>. Other relevant changes include the identification of 15 PTC variants and the distinction of follicular thyroid cancers (FTCs) into three subgroups (minimally invasive FTCs with capsular invasion only, encapsulated angioinvasive FTCs, and widely invasive FTCs), which reflect the prognostic relevance of vascular invasion. Given its unique molecular profile<sup><a href="#ref-4">4</a></sup>, the oncocytic variant is now considered a separate entity and is referred to as Hrthle cell carcinoma. Poorly differentiated thyroid cancer is also a separate entity, in accordance with the Turin criteria<sup><a href="#ref-5">5</a>,<a href="#ref-6">6</a></sup>.</p><p class="" id=d94018e224>The American Joint Cancer Committee/Union Internationale Contre le Cancer TNM staging system for thyroid cancer takes into account patient age, the size and extent of the primary thyroid tumor (T), lymph node involvement (N), and the presence of distant metastases (M). This system is aimed at predicting mortality (not recurrences). The eighth edition of this staging system contains important modifications. The age cutoff was raised from 45 to 55 years<sup><a href="#ref-7">7</a></sup>, the presence of minimal extrathyroidal extension is no longer relevant for the T classification, and the tumor stages have been redistributed (<a href="#T1">Table 1</a> and <a href="#T2">Table 2</a>). Regional lymph node metastases or the presence of gross extrathyroidal extension limited to strap muscle no longer mandate stage III but stage II. The presence of macroscopic invasion beyond strap muscle (subcutaneous tissue, larynx, trachea, esophagus in T4a tumors or carotid artery, prevertebral fascia or mediastinal vessels in T4b tumors) is an unfavorable prognostic factor. The overall goal of these modifications is to improve the accuracy of the systems prediction of mortality<sup><a href="#ref-8">8</a></sup>, restricting the assignment of higher risk to a small subset of patients (510%) with tumors classified as stage III (pT4a, any N, M0) or stage IV (pT4b, any N, M0, and M1). Implementation of the eighth edition revisions is expected to result in the down-staging of approximately 3040% of patients with thyroid cancer<sup><a href="#ref-9">9</a>,<a href="#ref-10">10</a></sup>.</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. AJCC TNM seventh and eighth edition: definitions.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d94018e259 class=n-a></a><thead><a name=d94018e261 class=n-a></a><tr><a name=d94018e263 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d94018e265 class=n-a></a>Seventh edition</th><th align=left colspan=1 rowspan=1 valign=top><a name=d94018e268 class=n-a></a>Eighth edition</th></tr></thead><tbody><a name=d94018e273 class=n-a></a><tr><a name=d94018e275 class=n-a></a><td align=center colspan=2 rowspan=1><a name=d94018e277 class=n-a></a> <b>Tumor</b> </td></tr><tr><a name=d94018e284 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e286 class=n-a></a> <b>T1a:</b> tumor 1 cm limited to the thyroid</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e292 class=n-a></a> <b>T1a:</b> tumor 1 cm limited to the thyroid</td></tr><tr><a name=d94018e299 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e301 class=n-a></a> <b>T1b:</b> tumor &gt;1 cm but 2 cm limited to the thyroid</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e307 class=n-a></a> <b>T1b:</b> tumor &gt;1 cm but 2 cm limited to the thyroid</td></tr><tr><a name=d94018e314 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e316 class=n-a></a> <b>T2:</b> tumor &gt;2 cm but 4 cm limited to the thyroid</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e322 class=n-a></a> <b>T2:</b> tumor &gt;2 cm but 4 cm limited to the thyroid</td></tr><tr><a name=d94018e329 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e331 class=n-a></a> <b>T3:</b> tumor &gt;4 cm limited to the thyroid or minimal extrathyroid<br class=br>extension (for example, perithyroidal soft tissues or sternothyroid<br class=br>muscle) from a tumor of any size</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e341 class=n-a></a> <b>T3a:</b> tumor &gt;4 cm limited to the thyroid<br class=br><br class=br><b>T3b:</b> gross extrathyroidal extension invading only strap muscles<br class=br>(sternohyoid, sternothyroid, thyrohyoid, omohyoid) from a tumor of<br class=br>any size</td></tr><tr><a name=d94018e358 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e360 class=n-a></a> <b>T4a:</b> gross extrathyroidal extension invading subcutaneous soft<br class=br>tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve<br class=br>from a tumor of any size</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e370 class=n-a></a> <b>T4a:</b> gross extrathyroidal extension invading subcutaneous soft<br class=br>tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve<br class=br>from a tumor of any size</td></tr><tr><a name=d94018e381 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e383 class=n-a></a> <b>T4b:</b> gross extrathyroidal extension invading prevertebral fascia or<br class=br>encasing the carotid artery or mediastinal vessels from a tumor of<br class=br>any size</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e393 class=n-a></a> <b>T4b:</b> gross extrathyroidal extension invading prevertebral fascia or<br class=br>encasing the carotid artery or mediastinal vessels from a tumor of<br class=br>any size</td></tr><tr><a name=d94018e404 class=n-a></a><td align=center colspan=2 rowspan=1><a name=d94018e406 class=n-a></a> <b>Node</b> </td></tr><tr><a name=d94018e413 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e415 class=n-a></a> <b>Nx:</b> regional lymph nodes cannot be assessed</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e421 class=n-a></a> <b>Nx:</b> regional lymph nodes cannot be assessed</td></tr><tr><a name=d94018e428 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e430 class=n-a></a> <b>N0:</b> no evidence of locoregional lymph node metastasis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e436 class=n-a></a> <b>N0a:</b> one or more cytologically or histologically confirmed benign<br class=br>lymph nodes<br class=br><br class=br><b>N0b:</b> no radiologic or clinical evidence of locoregional lymph node<br class=br>metastasis</td></tr><tr><a name=d94018e452 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e454 class=n-a></a> <b>N1a:</b> ipsilateral or bilateral metastasis to level VI (pretracheal,<br class=br>paratracheal, or prelaryngeal/Delphian) lymph nodes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e462 class=n-a></a> <b>N1a:</b> ipsilateral or bilateral metastasis to level VI or VII (pretracheal,<br class=br>paratracheal, or prelaryngeal/Delphian, or upper mediastinal) lymph<br class=br>nodes; this can be unilateral or bilateral disease</td></tr><tr><a name=d94018e474 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e476 class=n-a></a> <b>N1b:</b> metastasis to unilateral, bilateral, or contralateral lateral neck<br class=br>lymph nodes (levels I, II, III, IV, or V) or retropharyngeal or superior<br class=br>mediastinal lymph nodes (level VII)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e486 class=n-a></a> <b>N1b:</b> metastasis to unilateral, bilateral, or contralateral lateral neck<br class=br>lymph nodes (levels I, II, III, IV, or V) or retropharyngeal lymph<br class=br>nodes</td></tr><tr><a name=d94018e497 class=n-a></a><td align=center colspan=2 rowspan=1><a name=d94018e499 class=n-a></a> <b>Metastasis</b> </td></tr><tr><a name=d94018e506 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e508 class=n-a></a> <b>M0:</b> no distant metastasis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e514 class=n-a></a> <b>M0:</b> no distant metastasis</td></tr><tr><a name=d94018e521 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e523 class=n-a></a> <b>M1:</b> distant metastasis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e529 class=n-a></a> <b>M1:</b> distant metastasis</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d94018e540 class=n-a></a><p id=d94018e542> AJCC, American Joint Cancer Committee; TNM, tumor, node, and metastasis.</p></div></div></div><div class="table-wrap panel clearfix"><a name=T2 class=n-a></a><div class=caption><h3>Table 2. AJCC TNM seventh and eighth edition: stage.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d94018e559 class=n-a></a><thead><a name=d94018e561 class=n-a></a><tr><a name=d94018e563 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d94018e565 class=n-a></a>Seventh edition</th><th align=left colspan=3 rowspan=1 valign=top><a name=d94018e568 class=n-a></a>Age &lt;45 years</th><th align=left colspan=1 rowspan=1 valign=top><a name=d94018e571 class=n-a></a>Eighth edition</th><th align=left colspan=3 rowspan=1 valign=top><a name=d94018e574 class=n-a></a>Age &lt;55 years</th></tr></thead><tbody><a name=d94018e579 class=n-a></a><tr><a name=d94018e581 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e583 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e586 class=n-a></a>Any T</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e589 class=n-a></a>Any N</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e592 class=n-a></a>M0</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e595 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e599 class=n-a></a>Any T</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e602 class=n-a></a>Any N</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e605 class=n-a></a>M0</td></tr><tr><a name=d94018e609 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e611 class=n-a></a>II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e614 class=n-a></a>Any T</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e617 class=n-a></a>Any N</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e620 class=n-a></a>M1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e623 class=n-a></a>II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e627 class=n-a></a>Any T</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e630 class=n-a></a>Any N</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e633 class=n-a></a>M1</td></tr><tr><a name=d94018e637 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e639 class=n-a></a><b>Seventh edition</b></td><td align=left colspan=3 rowspan=1 valign=top><a name=d94018e643 class=n-a></a><b>Age 45 years</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e647 class=n-a></a><b>Eighth edition</b></td><td align=left colspan=3 rowspan=1 valign=top><a name=d94018e651 class=n-a></a><b>Age 55 years</b></td></tr><tr><a name=d94018e656 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e658 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e661 class=n-a></a>T1a/b</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e664 class=n-a></a>N0</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e667 class=n-a></a>M0</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e670 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e674 class=n-a></a>T1a/b<br class=br>T2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e679 class=n-a></a>N0/NX<br class=br>N0/NX</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e684 class=n-a></a>M0<br class=br>M0</td></tr><tr><a name=d94018e690 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e692 class=n-a></a>II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e695 class=n-a></a>T2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e698 class=n-a></a>N0</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e701 class=n-a></a>M0</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e704 class=n-a></a>II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e708 class=n-a></a>T1a/b<br class=br>T2<br class=br>T3a/b</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e715 class=n-a></a>N1a/b<br class=br>N1a/b<br class=br>Any N</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e722 class=n-a></a>M0<br class=br>M0<br class=br>M0</td></tr><tr><a name=d94018e731 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e733 class=n-a></a>III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e736 class=n-a></a>T1a/b<br class=br>T2<br class=br>T3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e743 class=n-a></a>N1a<br class=br>N1a<br class=br>N0, N1a</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e750 class=n-a></a>M0<br class=br>M0<br class=br>M0</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e757 class=n-a></a>III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e761 class=n-a></a>T4a</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e764 class=n-a></a>Any N</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e767 class=n-a></a>M0</td></tr><tr><a name=d94018e771 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e773 class=n-a></a>IVa</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e776 class=n-a></a>T1a/b<br class=br>T2<br class=br>T3<br class=br>T4a</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e785 class=n-a></a>N1b<br class=br>N1b<br class=br>N1b<br class=br>N0, N1a, N1b</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e794 class=n-a></a>M0<br class=br>M0<br class=br>M0<br class=br>M0</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e803 class=n-a></a>IVa</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e807 class=n-a></a>T4b</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e810 class=n-a></a>Any N</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e813 class=n-a></a>M0</td></tr><tr><a name=d94018e817 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e819 class=n-a></a>IVb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e822 class=n-a></a>T4b</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e825 class=n-a></a>Any N</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e828 class=n-a></a>M0</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e831 class=n-a></a>IVb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e835 class=n-a></a>Any T</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e838 class=n-a></a>Any N</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e841 class=n-a></a>M1</td></tr><tr><a name=d94018e845 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e847 class=n-a></a>IVc</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e850 class=n-a></a>Any T</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e853 class=n-a></a>Any T</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e856 class=n-a></a>M1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e859 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e863 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e866 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d94018e869 class=n-a></a>-</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d94018e877 class=n-a></a><p id=d94018e879> AJCC, American Joint Cancer Committee; TNM, tumor, node, and metastasis.</p></div></div></div><p class="" id=d94018e886>In the 2015 edition of its practice guidelines, the ATA also revised its system for stratifying the risk of recurrent disease. The new variables considered include new pathologic features of the tumor (for example, histopathological variant, vascular invasion, number of metastatic lymph nodes, size of the largest metastatic lymph node, and the presence of extranodal extension) as well as its molecular characteristics (mutational status of <i>BRAF</i> and the <i>TERT</i> promoter<sup><a href="#ref-11">11</a></sup>, when available)<sup><a href="#ref-12">12</a></sup>. These changes are expected to allow more precise estimates of the likelihood of recurrence.</p><p class="" id=d94018e903>The dynamic risk classification process used during follow-up assigns patients to one of four subgroups and may be modified at each follow-up examination: responses to therapy are classified as excellent, biochemically incomplete, structurally incomplete, or indeterminate response.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d94018e909>Management strategies</h2><p class="" id=d94018e912>Current international guidelines advocate personalized decision-makingbased on the risk of recurrence and disease-specific deathregarding the extent of surgery, the use of radioactive iodine (RAI) therapy, the intensity and length of follow-up, and the degree of thyroid-stimulating hormone (TSH) suppression.</p><div class=section><a name=d94018e915 class=n-a></a><h3 class=section-title>Active surveillance</h3><p class="" id=d94018e920>The 2015 ATA guidelines include active surveillance among the management options for small subcentimeter PTCs. In pivotal Japanese studies, this strategy appeared to be both safe and effective<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>: after 10 years, very few patients had experienced tumor growth (8%), and the development of lymph node metastases was even less common (4%). Age below 40 at diagnosis was an independent risk factor for disease progression<sup><a href="#ref-15">15</a></sup>. In terms of cures, delayed surgical treatment of these tumors was as effective as immediate treatment<sup><a href="#ref-15">15</a></sup>.</p><p class="" id=d94018e938>In a study conducted in the United States, 291 patients with cytologically suspicious or malignant thyroid nodules (Bethesda class V or VI) measuring 1.5 cm or less were managed with active surveillance for a median of two years<sup><a href="#ref-16">16</a></sup>. The percentages of tumors displaying growth were 2.5% at two years and 12% at five years. Independent predictors of growth were age under 50 years and clinical judgment as inappropriate for active surveillance<sup><a href="#ref-16">16</a></sup>. The latter label may be applied on the basis of nodule-related features (subcapsular location adjacent to the recurrent laryngeal nerve [RLN], suspicion of extrathyroidal extension, and invasion of the RLN or tracheaall three of which can be difficult to exclude on neck ultrasound [US]fine-needle aspiration [FNA] cytology findings suggestive of an aggressive histotype, and a documented increase in size of at least 3 mm in a confirmed PTC) or patient-related factors (metastatic disease, age below 18 years, refusal of the surveillance-alone approach, poor adherence to the follow-up protocol) or physician-related factors (limited experience with thyroid cancer management or neck US or both) or a combination of these factors<sup><a href="#ref-17">17</a></sup>.</p><p class="" id=d94018e953>Other observational clinical trials to evaluate the active surveillance approach in subcentimeter PTCs are underway in Korea and Israel (NCT02952612, NCT02938702, and NCT02609685). Also, there is a need for biomarkers that can identify those rare microcarcinomas that are likely to grow, so they can be promptly referred for surgery.</p></div><div class=section><a name=d94018e957 class=n-a></a><h3 class=section-title>Individualized surgical approaches</h3><p class="" id=d94018e962>According to the ATA guidelines<sup><a href="#ref-12">12</a></sup>, thyroid lobectomy (TL) may be used for low-risk, intrathyroidal tumors up to 4 cm in size with no lesions in the contralateral lobe. Total thyroidectomy (TT) was previously considered the preferred approach for these tumors. In a retrospective analysis of 52,173 cases in the Surveillance Epidemiology and End Results (SEER) database, TL for tumors measuring at least 1 cm was associated with small but statistically significant increases in the risks for recurrence (9.8% versus 7.7%) and mortality (2.9% versus 1.6%) compared with TT<sup><a href="#ref-18">18</a></sup>. A recent retrospective analysis with a more extensive risk stratification found no such difference in terms of overall survival<sup><a href="#ref-19">19</a></sup>, but, in another meta-analysis, the risk of recurrence after TL was significantly higher than that after TT (8.3% versus 4.4%; <i>p</i>&lt;0.01)<sup><a href="#ref-20">20</a></sup>. It is worth noting that tumor recurrence in the contralateral lobe has been observed in 5% of patients treated with TL<sup><a href="#ref-21">21</a></sup> and that benign nodule relapse is reported in 2050%<sup><a href="#ref-22">22</a>,<a href="#ref-23">23</a></sup>. Levothyroxine treatment has been reported to prevent benign nodule relapse, but the evidence for this effect is limited<sup><a href="#ref-24">24</a></sup>.</p><p class="" id=d94018e1000>TL offers several advantages over TT. First, the rate of side effects is lower with TL. It virtually eliminates the risks of permanent hypoparathyroidism and bilateral RLN palsy<sup><a href="#ref-25">25</a></sup> and reduces the rates of permanent unilateral RLN palsy (0.6% in TL versus 1.3% in TT)<sup><a href="#ref-25">25</a></sup>. Second, surgical hypothyroidism after TT requires lifelong levothyroxine (LT4) replacement therapy. The rate of hypothyroidism after TL varies from 23.6 to 47%<sup><a href="#ref-26">26</a>,<a href="#ref-27">27</a></sup>, and patients with a normal serum TSH level may not require LT4 treatment at all. TL and TT are also believed to have differential effects on the patients quality of life. However, two relatively small studies have failed to detect any difference<sup><a href="#ref-28">28</a>,<a href="#ref-29">29</a></sup> and thus further investigation of this issue is needed.</p><p class="" id=d94018e1025>The ATA guidelines do not advocate prophylactic central neck dissection for low-risk patients<sup><a href="#ref-12">12</a></sup> despite the high frequency of subclinical lymph node metastasis in DTC<sup><a href="#ref-30">30</a></sup>. In fact, microscopic lymph node metastases that are not clinically detected before surgery have a questionable role in patient outcome<sup><a href="#ref-31">31</a></sup>, and central compartment neck dissection carries an increased rate of surgical complications, hypoparathyroidism in particular<sup><a href="#ref-32">32</a>,<a href="#ref-33">33</a></sup>. In a prospective study of patients with no preoperative evidence of lymph node metastasis who were randomly assigned to undergo TT alone or TT with central compartment neck dissection, no difference in outcomes was found after five years of follow-up<sup><a href="#ref-32">32</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d94018e1055>Radioiodine remnant ablation: selective use</h2><p class="" id=d94018e1058>In the past, routine use of RAI ablation therapy after surgery was justified first by the need to eliminate residual normal thyroid tissue, to achieve an undetectable serum thyroglobulin (Tg) level. It also allowed the identification of persistent neoplastic tissue with a <sup>131</sup>I whole-body scan (WBS) and was likely to destroy any occult nests of neoplastic cells, thereby improving long-term outcomes. These indications have been questioned in recent years<sup><a href="#ref-12">12</a>,<a href="#ref-34">34</a>,<a href="#ref-35">35</a></sup>. The ATA guidelines now recommend selective use of RAI based on individual risk<sup><a href="#ref-12">12</a></sup>. Claiming uncertainties and ambiguities in the evidence, the European Association of Nuclear Medicine refused to endorse these recommendations<sup><a href="#ref-36">36</a></sup> and noted that there are no prospective, controlled study data that allow us to identify the patients with low-risk DTC who may not benefit from RAI ablation. However, the Association did not emphasize that a treatment should be given only in patients in whom it may be beneficial and did not acknowledge that uncertainties persist concerning benefits of RAI administration in low- and intermediate-risk patients.</p><p class="" id=d94018e1082>It is generally agreed that RAI has no role in the management of patients with intra-thyroidal microcarcinomas. In other low- and intermediate-risk patients, the decision to ablate can be based on individual prognostic factors and on the serum Tg level measured 6 weeks after surgery either on LT4 treatment with a sensitive assay or following recombinant human TSH (rhTSH) injections. An undetectable or a low serum Tg level at that time supports a decision to avoid RAI administration. When it is indicated, it should consist of the administration of 1.1 GBq following rhTSH injections<sup><a href="#ref-37">37</a></sup>.</p><p class="" id=d94018e1089>Two randomized clinical trials in Europe are enrolling low-risk patients and aim to obtain reliable data on the indications for post-operative RAI administration. In the ESTIMABL2 trial (NCT01837745) being conducted in France, 750 patients with a T1bN0,Nx tumor will be randomly assigned to post-operative ablation with an activity of 30 mCi after rhTSH stimulation or simple follow-up. The IoN trial in the UK (NCT01398085) has a similar design. The primary outcomes in the two studies are disease-free survival rates at 3 and 5 years, respectively.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d94018e1095>Follow-up tools</h2><p class="" id=d94018e1098>The main tools used for the follow-up of DTC are neck US and serum Tg determination<sup><a href="#ref-38">38</a></sup>. Undetectable serum Tg levels can reliably identify disease-free patients and have a negative predictive value close to 100%. In contrast, early minimally detectable levels have a low positive predictive value: the majority of patients with these findings remain free of structural disease during prolonged follow-up<sup><a href="#ref-39">39</a></sup>. Tg trends over timeinstead of absolute valuesshould be monitored: declining levels are reassuring, whereas increases suggest the presence of growing thyroid tissue (normal or neoplastic)<sup><a href="#ref-40">40</a></sup>. In the presence of Tg autoantibodies (TgAbs), serum Tg levels determined by immunometric assays may be falsely low. In these cases, management can be guided by the temporal trends in the TgAb titers themselves<sup><a href="#ref-41">41</a></sup>. Novel biomarkers are emerging as replacements for serum Tg in these difficult cases, such as circulating microRNAs and other nucleic acids, but still need to be standardized and clinically validated<sup><a href="#ref-42">42</a><a href="#ref-44">44</a></sup>. The use of mass spectrometry for measuring serum Tg levels in the presence of TgAb also needs to be validated<sup><a href="#ref-45">45</a>,<a href="#ref-46">46</a></sup>. Sensitive Tg assays that can detect serum concentrations as low as 0.1 ng/mL are currently used and provide similar information on disease status as rhTSH-stimulated Tg obtained in the past with assays that had a sensitivity of 1 ng/mL. RhTSH-stimulated Tg levels are now measured during the follow-up only in those few patients with low but detectable serum Tg on LT4 treatment<sup><a href="#ref-47">47</a></sup>. In these patients, a substantial increase in the stimulated Tg level may indicate the presence of neoplastic tissue.</p><p class="" id=d94018e1136>Neck US provides useful information. PTC almost always spreads first to the cervical lymph nodes, where it can be identified sonographically using specific criteria<sup><a href="#ref-48">48</a></sup>, thus eliminating the need for diagnostic <sup>131</sup>I WBS. US is more cost-effective, eliminates radiation exposure, and has no adverse effects. Surgical treatment of lymph node metastases is recommended for lesions with smaller diameters exceeding 10 mm (for lateral N1) or 8 mm (for central N1), and there is no need for discovering small N1 of only a few millimeters in diameter. However, US is notoriously operator-dependent, and some findings are non-specific and classified as indeterminate. Lesions with such features display significantly lower rates of persistence and growth than those with more suspicious US characteristics<sup><a href="#ref-49">49</a></sup>. Suspicious findings can be confirmed by US-guided FNA with cytologic assessment and assay of Tg in the needle-washout fluid<sup><a href="#ref-50">50</a></sup>. Distant metastases are rare in patients with negative findings on neck US. However, in the presence of rising Tg levels or suspicious clinical features, second-line functional (diagnostic <sup>131</sup>I WBS and 18-fluorodeoxyglucose positron emission tomography scan) or cross-sectional (computed tomography or magnetic resonance imaging) imaging studies may be performed<sup><a href="#ref-51">51</a></sup>.</p><p class="" id=d94018e1162>Risk assessment is a dynamic process: the response to therapy is re-assessed on the basis of findings at each follow-up visit and expressed as excellent, indeterminate, biochemically incomplete, or structurally incomplete<sup><a href="#ref-12">12</a>,<a href="#ref-39">39</a>,<a href="#ref-52">52</a></sup>. During long-term follow-up, even patients who initially displayed a high risk of persistent or recurrent disease can be re-classified as having lower-risk disease, and their follow-up program can be less intensive than originally planned. Lifelong surveillance is still recommended<sup><a href="#ref-12">12</a></sup>. However, over 75% of recurrent lesions are identified within the first five years of follow-up, and late recurrence is very unlikely in low- or intermediate-risk patients with excellent responses to treatment<sup><a href="#ref-53">53</a></sup>.</p><p class="" id=d94018e1183>TSH stimulates the proliferation of normal and neoplastic thyrocytes<sup><a href="#ref-54">54</a></sup>, and levothyroxine treatment significantly reduces DTC recurrence and cancer-related mortality<sup><a href="#ref-55">55</a></sup>. The optimal TSH level is unclear. TSH suppression increases the risk for atrial fibrillation and osteoporosis in older patients and the risk of angina in patients with ischemic heart disease<sup><a href="#ref-56">56</a></sup>. Suppressive therapy should take into account both the likelihood of complications and the risk of increasing tumor cell proliferation. For this reason, levothyroxine treatment is no longer recommended for low- and intermediate-risk patients with no evidence of disease. The goal in these cases is a serum TSH level within the normal range. Suppressive therapy is advocated only in patients with structural disease and no contraindications<sup><a href="#ref-12">12</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d94018e1206>Treatment of distant metastases</h2><p class="" id=d94018e1209>RAI (<sup>131</sup>I) is currently the first-line treatment for distant metastases that are RAI-avid. Traditionally, thyroid hormone withdrawal has been the preferred method of preparation for this type of patient because it is associated with higher neoplastic tissue uptake and slower clearance of RAI than that achieved with rhTSH preparation. Observational data have suggested that rhTSH preparation may also be effective in terms of response to treatment in these patients<sup><a href="#ref-57">57</a></sup>, but the evidence in support of this conclusion is currently insufficient to recommend rhTSH use in patients with metastatic DTC<sup><a href="#ref-12">12</a></sup>. The activity of RAI for the treatment of distant metastases can be calculated dosimetrically or a fixed empiric dose can be used. A large retrospective study of DTC patients with distant metastases found similar overall survival with the two approaches<sup><a href="#ref-58">58</a></sup> after adjustments for age and tumor burden<sup><a href="#ref-59">59</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d94018e1234>Radioactive iodine-refractory disease</h2><p class="" id=d94018e1237>RAI-refractory DTC is defined as persistent neoplastic tissue that does not take up RAI; disease characterized by heterogeneous RAI uptake (that is, some lesions are RAI-avid and others are not); or disease that progresses after RAI treatment despite RAI uptake<sup><a href="#ref-12">12</a></sup>. Specific molecular profiles are more likely to result in RAI-refractory disease<sup><a href="#ref-60">60</a>,<a href="#ref-61">61</a></sup>. Even in the presence of distant metastases, most patients have asymptomatic, slowly progressive disease. RAI-refractory patients should benefit from local treatments (surgery, external beam radiotherapy, or thermal ablation, depending on the site of the lesion and local expertise) if they have symptoms or a high risk of local complications.</p><p class="" id=d94018e1251>When disease progression occurs at multiple sites in patients with target lesions of more than 12 cm in diameter, treatment with tyrosine kinase inhibitors (TKIs) should be considered.</p><p class="" id=d94018e1254>Two multitarget TKIs have been approved for the treatment of RAI-refractory DTC in the United States and Europe: sorafenib and lenvatinib<sup><a href="#ref-62">62</a>,<a href="#ref-63">63</a></sup>. These drugs have been shown to prolong the progression-free survival of patients with progressive RAI-refractory DTC, as compared with placebo (10.8 versus 5.8 months, hazard ratio [HR] 0.59 for sorafenib; 18.3 versus 3.6 months, HR 0.21 for lenvatinib), and objective response rates were 12% and 65%, respectively<sup><a href="#ref-62">62</a>,<a href="#ref-63">63</a></sup>. However, multitarget TKIs have side effects<sup><a href="#ref-64">64</a></sup>. Greater experience in their use and better knowledge of the risk factors for these adverse effects<sup><a href="#ref-65">65</a>,<a href="#ref-66">66</a></sup> are likely to improve their tolerance.</p><p class="" id=d94018e1282>For BRAF- or ALK-mutant tumors, specific inhibitors may be used<sup><a href="#ref-64">64</a>,<a href="#ref-67">67</a></sup>. Treatments capable of restoring RAI uptake have attracted great interest. Selumetinib (a selective MEK inhibitor) and dabrafenib (a selective BRAF inhibitor used in BRAF-mutated tumors) have been shown to increase RAI uptake by RAI-refractory tumor tissues<sup><a href="#ref-68">68</a>,<a href="#ref-69">69</a></sup>, and these encouraging results are now under investigation (NCT02393690 and NCT03244956). Immunotherapy also appears to be a promising approach to thyroid cancer, alone or in association with other drugs<sup><a href="#ref-70">70</a></sup> (NCT02390739 and NCT03181100). These agents have yet to be approved by regulatory agencies, such as the U.S. Food and Drug Administration and the European Medicines Agency. Enrollment in clinical trials for patients with progressive metastatic disease should be considered and encouraged in order to improve both clinical case outcomes and medical knowledge in the field<sup><a href="#ref-71">71</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d94018e1310>Conclusions</h2><p class="" id=d94018e1313>In recent years, DTC treatment has become considerably more conservative, with less extensive surgery (or no surgery at all), reduced use of radioisotopes, and less intensive follow-up of low- and intermediate-risk patients. Furthermore, the systems used to histologically classify and stage DTCs have recently been refined, along with the ATA scheme for estimating their risk of recurrence, and more patients are now considered to be at low or intermediate risk. There is a need for new, prospective data to clarify how these changing practices will impact the long-term outcome of these patients. On the other hand, patients with more advanced or high-risk disease now have a broader portfolio of treatment options, including multitarget TKI therapy, more selective BRAF inhibitors, combination therapies, and immunotherapy. However, the indications for each, their optimal starting times and dosing schedules, and their long-term safety profiles remain to be clarified in coming years.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d94018e1319>Abbreviations</h2><p class="" id=d94018e1322>ATA, American Thyroid Association; DTC, differentiated thyroid carcinoma; FNA, fine-needle aspiration; FTC, follicular thyroid cancer; HR, hazard ratio; NIFTP, non-invasive follicular thyroid neoplasm with papillary nuclear features; PTC, papillary thyroid carcinoma; RAI, radioactive iodine; rhTSH, recombinant human thyroid-stimulating hormone; RLN, recurrent laryngeal nerve; Tg, thyroglobulin; TgAb, thyroglobulin autoantibody; TKI, tyrosine kinase inhibitor; TL, thyroid lobectomy; TNM, tumor, node, and metastasis; TSH, thyroid-stimulating hormone; TT, total thyroidectomy; US, ultrasound; WBS, whole-body scan.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d94018e1 class=n-a></a><h2 class=main-title id=d94261>Competing interests</h2><p class=metadata-entry><a name=d94018e120 class=n-a></a><p id=d94018e121> No competing interests were disclosed.</p></p></div><div class=back-section><a name=d94018e1 class=n-a></a><h2 class=main-title id=d94263>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d94018e1329 class=n-a></a><h2 class=main-title id=d94018e1331>Acknowledgments</h2><p class="" id=d94018e1334>GG and LL contributed to this article as recipients of the PhD program of Biotechnologies and Clinical Medicine of the Sapienza University of Rome.</p></div><div class=back-section><a name=d94018e1338 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d94505>References</h2><div class="section ref-list"><a name=d94018e1338 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d94018e1345 class=n-a></a>WHO Classification of Tumours of Endocrine Organs. Fourth Edition ed. Geneve: World Health Organization; 2017. <a target=xrefwindow id=d94018e1347 href="http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-Endocrine-Organs-2017">Reference Source</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727237674"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e1356 class=n-a></a>Haugen BR, Sawka AM, Alexander EK, <i> et al.</i>: American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. <i>Thyroid.</i> 2017; <b>27</b>(4): 4813. <a target=xrefwindow id=d94018e1367 href="http://www.ncbi.nlm.nih.gov/pubmed/28114862">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1370 href="http://dx.doi.org/10.1089/thy.2016.0628">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727237674">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d94018e1383 class=n-a></a>Nikiforov YE, Seethala RR, Tallini G, <i> et al.</i>: Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. <i>JAMA Oncol.</i> 2016; <b>2</b>(8): 10239. <a target=xrefwindow id=d94018e1394 href="http://www.ncbi.nlm.nih.gov/pubmed/27078145">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1397 href="http://dx.doi.org/10.1001/jamaoncol.2016.0386">Publisher Full Text </a> | <a target=xrefwindow id=d94018e1401 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5539411">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d94018e1410 class=n-a></a>Grani G, Lamartina L, Durante C, <i> et al.</i>: Follicular thyroid cancer and Hrthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. <i>Lancet Diabetes Endocrinol.</i> 2017;. pii: S2213-8587(17)30325-X. <a target=xrefwindow id=d94018e1418 href="http://www.ncbi.nlm.nih.gov/pubmed/29102432">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1421 href="http://dx.doi.org/10.1016/S2213-8587(17)30325-X">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d94018e1430 class=n-a></a>Volante M, Collini P, Nikiforov YE, <i> et al.</i>: Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. <i>Am J Surg Pathol.</i> 2007; <b>31</b>(8): 125664. <a target=xrefwindow id=d94018e1441 href="http://www.ncbi.nlm.nih.gov/pubmed/17667551">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1444 href="http://dx.doi.org/10.1097/PAS.0b013e3180309e6a">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d94018e1454 class=n-a></a>Volante M, Bussolati G, Papotti M: The story of poorly differentiated thyroid carcinoma: From Langhans' description to the Turin proposal via Juan Rosai. <i>Semin Diagn Pathol.</i> 2016; <b>33</b>(5): 27783. <a target=xrefwindow id=d94018e1462 href="http://www.ncbi.nlm.nih.gov/pubmed/27344303">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1465 href="http://dx.doi.org/10.1053/j.semdp.2016.05.007">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726172510"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e1474 class=n-a></a>Nixon IJ, Wang LY, Migliacci JC, <i> et al.</i>: An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer. <i>Thyroid.</i> 2016; <b>26</b>(3): 37380. <a target=xrefwindow id=d94018e1485 href="http://www.ncbi.nlm.nih.gov/pubmed/26914539">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1488 href="http://dx.doi.org/10.1089/thy.2015.0315">Publisher Full Text </a> | <a target=xrefwindow id=d94018e1492 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4790212">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726172510">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727790031"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e1505 class=n-a></a>Kim TH, Kim YN, Kim HI, <i> et al.</i>: Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma. <i>Oral Oncol.</i> 2017; <b>71</b>: 816. <a target=xrefwindow id=d94018e1516 href="http://www.ncbi.nlm.nih.gov/pubmed/28688696">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1519 href="http://dx.doi.org/10.1016/j.oraloncology.2017.06.004">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727790031">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727737795"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e1532 class=n-a></a>Kim M, Kim WG, Oh HS, <i> et al.</i>: Comparison of the Seventh and Eighth Editions of the American Joint Committee on Cancer/Union for International Cancer Control Tumor-Node-Metastasis Staging System for Differentiated Thyroid Cancer. <i>Thyroid.</i> 2017; <b>27</b>(9): 114955. <a target=xrefwindow id=d94018e1543 href="http://www.ncbi.nlm.nih.gov/pubmed/28635571">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1546 href="http://dx.doi.org/10.1089/thy.2017.0050">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727737795">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727576994"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e1559 class=n-a></a>Tuttle RM, Haugen B, Perrier ND: Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? <i>Thyroid.</i> 2017; <b>27</b>(6): 7516. <a target=xrefwindow id=d94018e1567 href="http://www.ncbi.nlm.nih.gov/pubmed/28463585">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1570 href="http://dx.doi.org/10.1089/thy.2017.0102">Publisher Full Text </a> | <a target=xrefwindow id=d94018e1573 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5467103">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727576994">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d94018e1586 class=n-a></a>de Biase D, Gandolfi G, Ragazzi M, <i> et al.</i>: <i>TERT</i> Promoter Mutations in Papillary Thyroid Microcarcinomas. <i>Thyroid.</i> 2015; <b>25</b>(9): 10139. <a target=xrefwindow id=d94018e1600 href="http://www.ncbi.nlm.nih.gov/pubmed/26148423">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1604 href="http://dx.doi.org/10.1089/thy.2015.0101">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725851631"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e1614 class=n-a></a>Haugen BR, Alexander EK, Bible KC, <i> et al.</i>: 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. <i>Thyroid.</i> 2016; <b>26</b>(1): 1133. <a target=xrefwindow id=d94018e1625 href="http://www.ncbi.nlm.nih.gov/pubmed/26462967">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1628 href="http://dx.doi.org/10.1089/thy.2015.0020">Publisher Full Text </a> | <a target=xrefwindow id=d94018e1632 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4739132">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725851631">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d94018e1645 class=n-a></a>Ito Y, Miyauchi A, Inoue H, <i> et al.</i>: An observational trial for papillary thyroid microcarcinoma in Japanese patients. <i>World J Surg.</i> 2010; <b>34</b>(1): 2835. <a target=xrefwindow id=d94018e1656 href="http://www.ncbi.nlm.nih.gov/pubmed/20020290">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1659 href="http://dx.doi.org/10.1007/s00268-009-0303-0">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725823332"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e1668 class=n-a></a>Oda H, Miyauchi A, Ito Y, <i> et al.</i>: Incidences of Unfavorable Events in the Management of Low-Risk Papillary Microcarcinoma of the Thyroid by Active Surveillance Versus Immediate Surgery. <i>Thyroid.</i> 2016; <b>26</b>(1): 1505. <a target=xrefwindow id=d94018e1679 href="http://www.ncbi.nlm.nih.gov/pubmed/26426735">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1682 href="http://dx.doi.org/10.1089/thy.2015.0313">Publisher Full Text </a> | <a target=xrefwindow id=d94018e1686 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4739129">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725823332">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718098820"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e1699 class=n-a></a>Ito Y, Miyauchi A, Kihara M, <i> et al.</i>: Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. <i>Thyroid.</i> 2014; <b>24</b>(1): 2734. <a target=xrefwindow id=d94018e1710 href="http://www.ncbi.nlm.nih.gov/pubmed/24001104">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1713 href="http://dx.doi.org/10.1089/thy.2013.0367">Publisher Full Text </a> | <a target=xrefwindow id=d94018e1717 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3887422">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718098820">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730364261"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e1730 class=n-a></a>Tuttle RM, Fagin JA, Minkowitz G, <i> et al.</i>: Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. <i>JAMA Otolaryngol Head Neck Surg.</i> 2017; <b>143</b>(10): 101520. <a target=xrefwindow id=d94018e1741 href="http://www.ncbi.nlm.nih.gov/pubmed/28859191">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1744 href="http://dx.doi.org/10.1001/jamaoto.2017.1442">Publisher Full Text </a> | <a target=xrefwindow id=d94018e1748 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5710258">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730364261">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725813906"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e1761 class=n-a></a>Brito JP, Ito Y, Miyauchi A, <i> et al.</i>: A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma. <i>Thyroid.</i> 2016; <b>26</b>(1): 1449. <a target=xrefwindow id=d94018e1772 href="http://www.ncbi.nlm.nih.gov/pubmed/26414743">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1775 href="http://dx.doi.org/10.1089/thy.2015.0178">Publisher Full Text </a> | <a target=xrefwindow id=d94018e1779 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4842944">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725813906">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d94018e1793 class=n-a></a>Bilimoria KY, Bentrem DJ, Ko CY, <i> et al.</i>: Extent of surgery affects survival for papillary thyroid cancer. <i>Ann Surg.</i> 2007; <b>246</b>(3): 37581; discussion 3814. <a target=xrefwindow id=d94018e1804 href="http://www.ncbi.nlm.nih.gov/pubmed/17717441">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1807 href="http://dx.doi.org/10.1097/SLA.0b013e31814697d9">Publisher Full Text </a> | <a target=xrefwindow id=d94018e1811 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1959355">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/723552818"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e1820 class=n-a></a>Adam MA, Pura J, Goffredo P, <i> et al.</i>: Impact of extent of surgery on survival for papillary thyroid cancer patients younger than 45 years. <i>J Clin Endocrinol Metab.</i> 2015; <b>100</b>(1): 11521. <a target=xrefwindow id=d94018e1831 href="http://www.ncbi.nlm.nih.gov/pubmed/25337927">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1834 href="http://dx.doi.org/10.1210/jc.2014-3039">Publisher Full Text </a> | <a target=xrefwindow id=d94018e1838 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5399499">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/723552818">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728170986"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e1851 class=n-a></a>Macedo FI, Mittal VK: Total thyroidectomy versus lobectomy as initial operation for small unilateral papillary thyroid carcinoma: A meta-analysis. <i>Surg Oncol.</i> 2015; <b>24</b>(2): 11722. <a target=xrefwindow id=d94018e1859 href="http://www.ncbi.nlm.nih.gov/pubmed/25956302">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1862 href="http://dx.doi.org/10.1016/j.suronc.2015.04.005">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728170986">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725947263"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e1875 class=n-a></a>Matsuzu K, Sugino K, Masudo K, <i> et al.</i>: Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. <i>World J Surg.</i> 2014; <b>38</b>(1): 6879. <a target=xrefwindow id=d94018e1886 href="http://www.ncbi.nlm.nih.gov/pubmed/24081532">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1889 href="http://dx.doi.org/10.1007/s00268-013-2224-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725947263">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d94018e1902 class=n-a></a>Antunes CM, Taveira-Gomes A: Lobectomy in follicular thyroid neoplasms' treatment. <i>Int J Surg.</i> 2013; <b>11</b>(9): 91922. <a target=xrefwindow id=d94018e1910 href="http://www.ncbi.nlm.nih.gov/pubmed/23863688">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1913 href="http://dx.doi.org/10.1016/j.ijsu.2013.07.004">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726307655"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e1922 class=n-a></a>Lytrivi M, Kyrilli A, Burniat A, <i> et al.</i>: Thyroid lobectomy is an effective option for unilateral benign nodular disease. <i>Clin Endocrinol (Oxf).</i> 2016; <b>85</b>(4): 6028. <a target=xrefwindow id=d94018e1933 href="http://www.ncbi.nlm.nih.gov/pubmed/27106627">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1936 href="http://dx.doi.org/10.1111/cen.13088">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726307655">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d94018e1950 class=n-a></a>Alba M, Fintini D, Lovicu RM, <i> et al.</i>: Levothyroxine therapy in preventing nodular recurrence after hemithyroidectomy: a retrospective study. <i>J Endocrinol Invest.</i> 2009; <b>32</b>(4): 3304. <a target=xrefwindow id=d94018e1961 href="http://www.ncbi.nlm.nih.gov/pubmed/19636201">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1964 href="http://dx.doi.org/10.1007/BF03345722">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d94018e1973 class=n-a></a>Rosato L, Avenia N, Bernante P, <i> et al.</i>: Complications of thyroid surgery: analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years. <i>World J Surg.</i> 2004; <b>28</b>(3): 2716. <a target=xrefwindow id=d94018e1984 href="http://www.ncbi.nlm.nih.gov/pubmed/14961204">PubMed Abstract </a> | <a target=xrefwindow id=d94018e1987 href="http://dx.doi.org/10.1007/s00268-003-6903-1">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d94018e1996 class=n-a></a>Balentine CJ, Domingo RP, Patel R, <i> et al.</i>: Thyroid lobectomy for indeterminate FNA: not without consequences. <i>J Surg Res.</i> 2013; <b>184</b>(1): 18992. <a target=xrefwindow id=d94018e2007 href="http://www.ncbi.nlm.nih.gov/pubmed/23777982">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2010 href="http://dx.doi.org/10.1016/j.jss.2013.05.076">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d94018e2019 class=n-a></a>Lee DY, Seok J, Jeong WJ, <i> et al.</i>: Prediction of thyroid hormone supplementation after thyroid lobectomy. <i>J Surg Res.</i> 2015; <b>193</b>(1): 2738. <a target=xrefwindow id=d94018e2030 href="http://www.ncbi.nlm.nih.gov/pubmed/25088372">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2033 href="http://dx.doi.org/10.1016/j.jss.2014.07.003">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d94018e2042 class=n-a></a>Malterling RR, Andersson RE, Falkmer S, <i> et al.</i>: Differentiated thyroid cancer in a Swedish county--long-term results and quality of life. <i>Acta Oncol.</i> 2010; <b>49</b>(4): 4549. <a target=xrefwindow id=d94018e2053 href="http://www.ncbi.nlm.nih.gov/pubmed/20092427">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2056 href="http://dx.doi.org/10.3109/02841860903544600">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d94018e2065 class=n-a></a>Shah MD, Witterick IJ, Eski SJ, <i> et al.</i>: Quality of life in patients undergoing thyroid surgery. <i>J Otolaryngol.</i> 2006; <b>35</b>(4): 20915. <a target=xrefwindow id=d94018e2076 href="http://www.ncbi.nlm.nih.gov/pubmed/17176794">PubMed Abstract </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d94018e2086 class=n-a></a>Wada N, Duh QY, Sugino K, <i> et al.</i>: Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. <i>Ann Surg.</i> 2003; <b>237</b>(3): 399407. <a target=xrefwindow id=d94018e2097 href="http://www.ncbi.nlm.nih.gov/pubmed/12616125">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2100 href="http://dx.doi.org/10.1097/01.SLA.0000055273.58908.19">Publisher Full Text </a> | <a target=xrefwindow id=d94018e2104 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1514312">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d94018e2113 class=n-a></a>Randolph GW, Duh Q, Heller KS, <i> et al.</i>: The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. <i>Thyroid.</i> 2012; <b>22</b>(11): 114452. <a target=xrefwindow id=d94018e2124 href="http://www.ncbi.nlm.nih.gov/pubmed/23083442">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2127 href="http://dx.doi.org/10.1089/thy.2012.0043">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d94018e2136 class=n-a></a>Viola D, Materazzi G, Valerio L, <i> et al.</i>: Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. <i>J Clin Endocrinol Metab.</i> 2015; <b>100</b>(4): 131624. <a target=xrefwindow id=d94018e2147 href="http://www.ncbi.nlm.nih.gov/pubmed/25590215">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2150 href="http://dx.doi.org/10.1210/jc.2014-3825">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d94018e2159 class=n-a></a>Lee DY, Oh KH, Cho JG, <i> et al.</i>: The Benefits and Risks of Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma: Prospective Cohort Study. <i>Int J Endocrinol.</i> 2015; <b>2015</b>: 571480. <a target=xrefwindow id=d94018e2170 href="http://www.ncbi.nlm.nih.gov/pubmed/26246805">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2173 href="http://dx.doi.org/10.1155/2015/571480">Publisher Full Text </a> | <a target=xrefwindow id=d94018e2177 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4515503">Free Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/722104497"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e2186 class=n-a></a>American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, <i> et al.</i>: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. <i>Thyroid.</i> 2009; <b>19</b>(11): 1167214. <a target=xrefwindow id=d94018e2197 href="http://www.ncbi.nlm.nih.gov/pubmed/19860577">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2200 href="http://dx.doi.org/10.1089/thy.2009.0110">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/722104497">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d94018e2213 class=n-a></a>Lamartina L, Durante C, Filetti S, <i> et al.</i>: Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. <i>J Clin Endocrinol Metab.</i> 2015; <b>100</b>(5): 174861. <a target=xrefwindow id=d94018e2224 href="http://www.ncbi.nlm.nih.gov/pubmed/25679996">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2227 href="http://dx.doi.org/10.1210/jc.2014-3882">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726157250"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e2237 class=n-a></a>Verburg FA, Aktolun C, Chiti A, <i> et al.</i>: Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. <i>Eur J Nucl Med Mol Imaging.</i> 2016; <b>43</b>(6): 10015. <a target=xrefwindow id=d94018e2248 href="http://www.ncbi.nlm.nih.gov/pubmed/26883666">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2251 href="http://dx.doi.org/10.1007/s00259-016-3327-3">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726157250">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/716147815"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e2264 class=n-a></a>Schlumberger M, Catargi B, Borget I, <i> et al.</i>: Strategies of radioiodine ablation in patients with low-risk thyroid cancer. <i>N Engl J Med.</i> 2012; <b>366</b>(18): 166373. <a target=xrefwindow id=d94018e2275 href="http://www.ncbi.nlm.nih.gov/pubmed/22551127">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2278 href="http://dx.doi.org/10.1056/NEJMoa1108586">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/716147815">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d94018e2291 class=n-a></a>Durante C, Attard M, Torlontano M, <i> et al.</i>: Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas. <i>J Clin Endocrinol Metab.</i> 2010; <b>95</b>(11): 48828. <a target=xrefwindow id=d94018e2302 href="http://www.ncbi.nlm.nih.gov/pubmed/20660054">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2305 href="http://dx.doi.org/10.1210/jc.2010-0762">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d94018e2314 class=n-a></a>Vaisman F, Momesso D, Bulzico DA, <i> et al.</i>: Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. <i>Clin Endocrinol (Oxf).</i> 2012; <b>77</b>(1): 1328. <a target=xrefwindow id=d94018e2325 href="http://www.ncbi.nlm.nih.gov/pubmed/22248037">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2328 href="http://dx.doi.org/10.1111/j.1365-2265.2012.04342.x">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d94018e2337 class=n-a></a>Durante C, Montesano T, Attard M, <i> et al.</i>: Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? <i>J Clin Endocrinol Metab.</i> 2012; <b>97</b>(8): 274853. <a target=xrefwindow id=d94018e2348 href="http://www.ncbi.nlm.nih.gov/pubmed/22679061">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2351 href="http://dx.doi.org/10.1210/jc.2012-1123">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d94018e2360 class=n-a></a>Durante C, Tognini S, Montesano T, <i> et al.</i>: Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies. <i>Thyroid.</i> 2014; <b>24</b>(7): 113945. <a target=xrefwindow id=d94018e2371 href="http://www.ncbi.nlm.nih.gov/pubmed/24702238">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2374 href="http://dx.doi.org/10.1089/thy.2013.0698">Publisher Full Text </a> | <a target=xrefwindow id=d94018e2378 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4080868">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d94018e2388 class=n-a></a>Rosignolo F, Memeo L, Monzani F, <i> et al.</i>: MicroRNA-based molecular classification of papillary thyroid carcinoma. <i>Int J Oncol.</i> 2017; <b>50</b>(5): 176777. <a target=xrefwindow id=d94018e2399 href="http://www.ncbi.nlm.nih.gov/pubmed/28393181">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2402 href="http://dx.doi.org/10.3892/ijo.2017.3960">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d94018e2411 class=n-a></a>Rosignolo F, Sponziello M, Giacomelli L, <i> et al.</i>: Identification of Thyroid-Associated Serum microRNA Profiles and Their Potential Use in Thyroid Cancer Follow-Up. <i>J Endocr Soc.</i> 2017; <b>1</b>(1): 313. <a target=xrefwindow id=d94018e2422 href="http://www.ncbi.nlm.nih.gov/pubmed/29264441">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2425 href="http://dx.doi.org/10.1210/js.2016-1032">Publisher Full Text </a> | <a target=xrefwindow id=d94018e2429 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5677215">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732004449"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e2438 class=n-a></a>Celano M, Rosignolo F, Maggisano V, <i> et al.</i>: MicroRNAs as Biomarkers in Thyroid Carcinoma. <i>Int J Genomics.</i> 2017; <b>2017</b>: 6496570. <a target=xrefwindow id=d94018e2449 href="http://www.ncbi.nlm.nih.gov/pubmed/29038786">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2452 href="http://dx.doi.org/10.1155/2017/6496570">Publisher Full Text </a> | <a target=xrefwindow id=d94018e2456 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5606057">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732004449">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725563140"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e2469 class=n-a></a>Netzel BC, Grebe SK, Carranza Leon BG, <i> et al.</i>: Thyroglobulin (Tg) Testing Revisited: Tg Assays, TgAb Assays, and Correlation of Results With Clinical Outcomes. <i>J Clin Endocrinol Metab.</i> 2015; <b>100</b>(8): E107483. <a target=xrefwindow id=d94018e2480 href="http://www.ncbi.nlm.nih.gov/pubmed/26079778">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2483 href="http://dx.doi.org/10.1210/jc.2015-1967">Publisher Full Text </a> | <a target=xrefwindow id=d94018e2487 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4524993">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725563140">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726840983"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e2500 class=n-a></a>Azmat U, Porter K, Senter L, <i> et al.</i>: Thyroglobulin Liquid Chromatography-Tandem Mass Spectrometry Has a Low Sensitivity for Detecting Structural Disease in Patients with Antithyroglobulin Antibodies. <i>Thyroid.</i> 2017; <b>27</b>(1): 7480. <a target=xrefwindow id=d94018e2511 href="http://www.ncbi.nlm.nih.gov/pubmed/27736322">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2514 href="http://dx.doi.org/10.1089/thy.2016.0210">Publisher Full Text </a> | <a target=xrefwindow id=d94018e2518 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5206681">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726840983">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/9701956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e2531 class=n-a></a>Brassard M, Borget I, Edet-Sanson A, <i> et al.</i>: Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. <i>J Clin Endocrinol Metab.</i> 2011; <b>96</b>(5): 13529. <a target=xrefwindow id=d94018e2542 href="http://www.ncbi.nlm.nih.gov/pubmed/21389143">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2545 href="http://dx.doi.org/10.1210/jc.2010-2708">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/9701956">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d94018e2559 class=n-a></a>Leenhardt L, Erdogan MF, Hegedus L, <i> et al.</i>: 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. <i>Eur Thyroid J.</i> 2013; <b>2</b>(3): 14759. <a target=xrefwindow id=d94018e2570 href="http://www.ncbi.nlm.nih.gov/pubmed/24847448">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2573 href="http://dx.doi.org/10.1159/000354537">Publisher Full Text </a> | <a target=xrefwindow id=d94018e2577 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4017749">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d94018e2586 class=n-a></a>Lamartina L, Grani G, Biffoni M, <i> et al.</i>: Risk Stratification of Neck Lesions Detected Sonographically During the Follow-Up of Differentiated Thyroid Cancer. <i>J Clin Endocrinol Metab.</i> 2016; <b>101</b>(8): 303644. <a target=xrefwindow id=d94018e2597 href="http://www.ncbi.nlm.nih.gov/pubmed/27186860">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2600 href="http://dx.doi.org/10.1210/jc.2016-1440">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d94018e2609 class=n-a></a>Grani G, Fumarola A: Thyroglobulin in lymph node fine-needle aspiration washout: a systematic review and meta-analysis of diagnostic accuracy. <i>J Clin Endocrinol Metab.</i> 2014; <b>99</b>(6): 197082. <a target=xrefwindow id=d94018e2617 href="http://www.ncbi.nlm.nih.gov/pubmed/24617715">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2620 href="http://dx.doi.org/10.1210/jc.2014-1098">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d94018e2629 class=n-a></a>Lamartina L, Deandreis D, Durante C, <i> et al.</i>: ENDOCRINE TUMOURS: Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach. <i>Eur J Endocrinol.</i> 2016; <b>175</b>(5): R185202. <a target=xrefwindow id=d94018e2640 href="http://www.ncbi.nlm.nih.gov/pubmed/27252484">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2643 href="http://dx.doi.org/10.1530/EJE-16-0088">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/8186977"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e2652 class=n-a></a>Tuttle RM, Tala H, Shah J, <i> et al.</i>: Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. <i>Thyroid.</i> 2010; <b>20</b>(12): 13419. <a target=xrefwindow id=d94018e2663 href="http://www.ncbi.nlm.nih.gov/pubmed/21034228">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2666 href="http://dx.doi.org/10.1089/thy.2010.0178">Publisher Full Text </a> | <a target=xrefwindow id=d94018e2670 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4845674">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/8186977">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d94018e2683 class=n-a></a>Durante C, Montesano T, Torlontano M, <i> et al.</i>: Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. <i>J Clin Endocrinol Metab.</i> 2013; <b>98</b>(2): 63642. <a target=xrefwindow id=d94018e2694 href="http://www.ncbi.nlm.nih.gov/pubmed/23293334">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2697 href="http://dx.doi.org/10.1210/jc.2012-3401">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d94018e2707 class=n-a></a>Biondi B, Filetti S, Schlumberger M: Thyroid-hormone therapy and thyroid cancer: a reassessment. <i>Nat Clin Pract Endocrinol Metab.</i> 2005; <b>1</b>(1): 3240. <a target=xrefwindow id=d94018e2715 href="http://www.ncbi.nlm.nih.gov/pubmed/16929364">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2718 href="http://dx.doi.org/10.1038/ncpendmet0020">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d94018e2727 class=n-a></a>Mazzaferri EL, Kloos RT: Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. <i>J Clin Endocrinol Metab.</i> 2001; <b>86</b>(4): 144763. <a target=xrefwindow id=d94018e2735 href="http://www.ncbi.nlm.nih.gov/pubmed/11297567">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2738 href="http://dx.doi.org/10.1210/jcem.86.4.7407">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d94018e2747 class=n-a></a>Biondi B, Cooper DS: Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. <i>Thyroid.</i> 2010; <b>20</b>(2): 13546. <a target=xrefwindow id=d94018e2755 href="http://www.ncbi.nlm.nih.gov/pubmed/20151821">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2758 href="http://dx.doi.org/10.1089/thy.2009.0311">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d94018e2767 class=n-a></a>Klubo-Gwiezdzinska J, Burman KD, van Nostrand D, <i> et al.</i>: Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer. <i>Endocr Pract.</i> 2013; <b>19</b>(1): 13948. <a target=xrefwindow id=d94018e2778 href="http://www.ncbi.nlm.nih.gov/pubmed/23186979">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2781 href="http://dx.doi.org/10.4158/EP12244.RA">Publisher Full Text </a> | <a target=xrefwindow id=d94018e2785 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4185285">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726848526"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e2794 class=n-a></a>Deandreis D, Rubino C, Tala H, <i> et al.</i>: Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer. <i>J Nucl Med.</i> 2017; <b>58</b>(5): 71722. <a target=xrefwindow id=d94018e2805 href="http://www.ncbi.nlm.nih.gov/pubmed/27738010">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2808 href="http://dx.doi.org/10.2967/jnumed.116.179606">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726848526">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d94018e2821 class=n-a></a>Durante C, Haddy N, Baudin E, <i> et al.</i>: Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. <i>J Clin Endocrinol Metab.</i> 2006; <b>91</b>(8): 28929. <a target=xrefwindow id=d94018e2832 href="http://www.ncbi.nlm.nih.gov/pubmed/16684830">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2835 href="http://dx.doi.org/10.1210/jc.2005-2838">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d94018e2845 class=n-a></a>Xing M, Westra WH, Tufano RP, <i> et al.</i>: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. <i>J Clin Endocrinol Metab.</i> 2005; <b>90</b>(12): 63739. <a target=xrefwindow id=d94018e2856 href="http://www.ncbi.nlm.nih.gov/pubmed/16174717">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2859 href="http://dx.doi.org/10.1210/jc.2005-0987">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d94018e2868 class=n-a></a>Durante C, Puxeddu E, Ferretti E, <i> et al.</i>: BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. <i>J Clin Endocrinol Metab.</i> 2007; <b>92</b>(7): 28403. <a target=xrefwindow id=d94018e2879 href="http://www.ncbi.nlm.nih.gov/pubmed/17488796">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2882 href="http://dx.doi.org/10.1210/jc.2006-2707">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725353054"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e2891 class=n-a></a>Schlumberger M, Tahara M, Wirth LJ, <i> et al.</i>: Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. <i>N Engl J Med.</i> 2015; <b>372</b>(7): 62130. <a target=xrefwindow id=d94018e2902 href="http://www.ncbi.nlm.nih.gov/pubmed/25671254">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2905 href="http://dx.doi.org/10.1056/NEJMoa1406470">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725353054">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d94018e2918 class=n-a></a>Brose MS, Nutting CM, Jarzab B, <i> et al.</i>: Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. <i>Lancet.</i> 2014; <b>384</b>(9940): 31928. <a target=xrefwindow id=d94018e2929 href="http://www.ncbi.nlm.nih.gov/pubmed/24768112">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2932 href="http://dx.doi.org/10.1016/S0140-6736(14)60421-9">Publisher Full Text </a> | <a target=xrefwindow id=d94018e2936 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4366116">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d94018e2945 class=n-a></a>Cabanillas ME, McFadden DG, Durante C: Thyroid cancer. <i>Lancet.</i> 2016; <b>388</b>(10061): 278395. <a target=xrefwindow id=d94018e2953 href="http://www.ncbi.nlm.nih.gov/pubmed/27240885">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2956 href="http://dx.doi.org/10.1016/S0140-6736(16)30172-6">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d94018e2965 class=n-a></a>Lamartina L, Ippolito S, Danis M, <i> et al.</i>: Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer. <i>J Clin Endocrinol Metab.</i> 2016; <b>101</b>(7): 273341. <a target=xrefwindow id=d94018e2976 href="http://www.ncbi.nlm.nih.gov/pubmed/27082933">PubMed Abstract </a> | <a target=xrefwindow id=d94018e2979 href="http://dx.doi.org/10.1210/jc.2015-4391">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d94018e2989 class=n-a></a>Blevins DP, Dadu R, Hu M, <i> et al.</i>: Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. <i>Thyroid.</i> 2014; <b>24</b>(5): 91822. <a target=xrefwindow id=d94018e3000 href="http://www.ncbi.nlm.nih.gov/pubmed/24635127">PubMed Abstract </a> | <a target=xrefwindow id=d94018e3003 href="http://dx.doi.org/10.1089/thy.2012.0598">Publisher Full Text </a> | <a target=xrefwindow id=d94018e3007 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4026371">Free Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725271952"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e3016 class=n-a></a>Cabanillas ME, Patel A, Danysh BP, <i> et al.</i>: : BRAF inhibitors: experience in thyroid cancer and general review of toxicity. <i>Horm Cancer.</i> 2015; <b>6</b>(1): 2136. <a target=xrefwindow id=d94018e3027 href="http://www.ncbi.nlm.nih.gov/pubmed/25467940">PubMed Abstract </a> | <a target=xrefwindow id=d94018e3030 href="http://dx.doi.org/10.1007/s12672-014-0207-9">Publisher Full Text </a> | <a target=xrefwindow id=d94018e3034 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4312215">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725271952">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717979607"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e3047 class=n-a></a>Ho AL, Grewal RK, Leboeuf R, <i> et al.</i>: Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. <i>N Engl J Med.</i> 2013; <b>368</b>(7): 62332. <a target=xrefwindow id=d94018e3058 href="http://www.ncbi.nlm.nih.gov/pubmed/23406027">PubMed Abstract </a> | <a target=xrefwindow id=d94018e3061 href="http://dx.doi.org/10.1056/NEJMoa1209288">Publisher Full Text </a> | <a target=xrefwindow id=d94018e3065 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3615415">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717979607">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726020312"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e3078 class=n-a></a>Rothenberg SM, Daniels GH, Wirth LJ: Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Response. <i>Clin Cancer Res.</i> 2015; <b>21</b>(24): 56401. <a target=xrefwindow id=d94018e3086 href="http://www.ncbi.nlm.nih.gov/pubmed/26672087">PubMed Abstract </a> | <a target=xrefwindow id=d94018e3089 href="http://dx.doi.org/10.1158/1078-0432.CCR-15-2298">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726020312">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726881202"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d94018e3102 class=n-a></a>French JD, Bible K, Spitzweg C, <i> et al.</i>: Leveraging the immune system to treat advanced thyroid cancers. <i>Lancet Diabetes Endocrinol.</i> 2017; <b>5</b>(6): 46981. <a target=xrefwindow id=d94018e3113 href="http://www.ncbi.nlm.nih.gov/pubmed/27773653">PubMed Abstract </a> | <a target=xrefwindow id=d94018e3116 href="http://dx.doi.org/10.1016/S2213-8587(16)30277-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726881202">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d94018e3129 class=n-a></a>Bible KC, Cote GJ, Demeure MJ, <i> et al.</i>: Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group. <i>J Clin Endocrinol Metab.</i> 2015; <b>100</b>(12): 438795. <a target=xrefwindow id=d94018e3140 href="http://www.ncbi.nlm.nih.gov/pubmed/26418285">PubMed Abstract </a> | <a target=xrefwindow id=d94018e3143 href="http://dx.doi.org/10.1210/jc.2015-2818">Publisher Full Text </a> | <a target=xrefwindow id=d94018e3147 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5399506">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 18 Jan 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-86&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-86&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Dipartimento di Medicina Interna e Specialit&agrave; Mediche, Universit&agrave; di Roma &ldquo;Sapienza&rdquo;, Viale del Policlinico 155, 00161 Rome, Italy<br/> <p> <div class=margin-bottom> Livia Lamartina <br/> <span>Roles: </span> Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Giorgio Grani <br/> <span>Roles: </span> Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Cosimo Durante <br/> <span>Roles: </span> Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Sebastiano Filetti <br/> <span>Roles: </span> Supervision, Writing  Original Draft Preparation, Writing  Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-86/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 18 Jan 2018, 7:86 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.12811.1">https://doi.org/10.12688/f1000research.12811.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2018 Lamartina L <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=13881 data-id=12811 data-downloads="" data-views="" data-scholar="10.12688/f1000research.12811.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-86/v1/pdf?article_uuid=85966746-a33e-4e9e-b337-64a20342bf84" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.12811.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Lamartina L, Grani G, Durante C and Filetti S. Recent advances in managing differentiated thyroid cancer [version 1; peer review: 2 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):86 (<a href="https://doi.org/10.12688/f1000research.12811.1" target=_blank>https://doi.org/10.12688/f1000research.12811.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=12811 id=mobile-track-article-signin-12811 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/12811?target=/articles/7-86"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=13881 /> <input name=articleId type=hidden value=12811 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Matthew Ringel</strong>, Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University Medical Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Iain Nixon</strong>, Ear, nose and throat (ENT) Department, NHS Lothian, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 18 Jan 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-86&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-86&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=27816-29983></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=27815-29982></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-86/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>18 Jan 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Matthew Ringel</strong>, Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University Medical Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Iain Nixon</strong>, Ear, nose and throat (ENT) Department, NHS Lothian, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-86&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-86/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in managing differentiated...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-86/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-86/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-86/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Lamartina L et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-86/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-86",
            templates : {
                twitter : "Recent advances in managing differentiated thyroid cancer. Lamartina L et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-86/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in managing differentiated thyroid cancer", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in managing differentiated thyroid cancer", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/12811/13881")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "13881");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "29980": 0,
                           "29981": 0,
                           "29982": 0,
                           "29983": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "1e27675a-e89b-4831-856a-bf489c4916ee";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-86.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-86.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-86.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-86.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-86.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>